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This study comprehensively deﬁnes the clinical association
between intestinal permeability increases and nonalcoholic
steatohepatitis. The results suggest that early-phase hepatic
injury and inﬂammation contribute to altered intestinal
permeability in a fashion independent of tumor necrosis
factor-a and myosin light chain kinase.
BACKGROUND & AIMS: Emerging data suggest that changes in
intestinal permeability and increased gut microbial trans-
location contribute to the inﬂammatory pathway involved in
nonalcoholic steatohepatitis (NASH) development. Numerous
studies have investigated the association between increased
intestinal permeability and NASH. Our meta-analysis of this
association investigates the underlying mechanism.
METHODS: A meta-analysis was performed to compare the
rates of increased intestinal permeability in patients with NASH
and healthy controls. To further address the underlying mech-
anism of action, we studied changes in intestinal permeability in
a diet-induced (methionine-and-choline-deﬁcient; MCD) murine
model of NASH. In vitro studies were also performed to inves-
tigate the effect of MCD culture medium at the cellular level on
hepatocytes, Kupffer cells, and intestinal epithelial cells.
RESULTS: Nonalcoholic fatty liver disease (NAFLD) patients,
and in particular those with NASH, are more likely to have
increased intestinal permeability compared with healthy con-
trols. We correlate this clinical observation with in vivo data
showing mice fed an MCD diet develop intestinal permeability
changes after an initial phase of liver injury and tumor necrosis
factor-a (TNFa) induction. In vitro studies reveal that MCD
medium induces hepatic injury and TNFa production yet has no
direct effect on intestinal epithelial cells. Although these data
suggest a role for hepatic TNFa in altering intestinal perme-
ability, we found that mice genetically resistant to TNFa-myosin
light chain kinase (MLCK)–induced intestinal permeability
changes fed an MCD diet still develop increased permeability
and liver injury.
CONCLUSIONS: Our clinical and experimental results
strengthen the association between intestinal permeabilityincreases and NASH and also suggest that an early phase of
hepatic injury and inﬂammation contributes to altered intesti-
nal permeability in a fashion independent of TNFa and MLCK.
(Cell Mol Gastroenterol Hepatol 2015;1:222–232; http://
dx.doi.org/10.1016/j.jcmgh.2015.01.001)
Keywords: Meta-Analysis; Myosin Light Chain Kinase; Steatosis;
Tight Junctions.
onalcoholic fatty liver disease (NAFLD) has becomeNan increasingly common clinical condition, with an
estimated prevalence of 30% in the U.S. population.1 Despite
this high prevalence, only a minority of NAFLD patients
develop nonalcoholic steatohepatitis (NASH) and ﬁbrosis,
which account for signiﬁcant morbidity and mortality.2 The
clinical challenge remains identifying the patients who are
more likely to develop NASH, as these patients are at greater
risk for liver-related adverse events. Unfortunately, to date
there is no reliable predictor of progression to NASH, nor are
therapies approved by the U.S. Food andDrug Administration
for this condition. Accordingly, a more fundamental under-
standing of the pathophysiology of NASH is critical to help
identify high-risk NAFLD patients and therapeutic targets.
There are accumulating data that suggest a role for al-
terations in intestinal permeability in the pathogenesis of
NASH. Speciﬁcally, it is hypothesized that an increase in in-
testinal epithelial cell permeability allows for translocation of
March 2015 Intestinal Permeability and NASH 223microbial products into the portal vein, which propagate
inﬂammation in a susceptible liver primed for injury.3,4 These
data suggest that communication between the intestine and
liver, the so-called gut-liver axis, plays a role in NASH
development. Accordingly, there is building momentum to
study the contribution of changes in intestinal homeostasis to
liver injury and inﬂammation.
Although our understanding of the gut-liver axis is
rapidly evolving, there remain many unanswered questions.
Multiple studies have examined have examined the inci-
dence of intestinal permeability changes in NASH patients;
however, a comprehensive and systemic assessment of this
relationship has yet to be performed. Furthermore, the
inciting event responsible for intestinal permeability
changes in patients with primary liver disease has not been
identiﬁed. Obesity is common in patients with NASH and has
been associated with intestinal inﬂammation and up-
regulation of tumor necrosis factor-a (TNFa), both of
which may contribute to intestinal leakage of microbial
products.5 Additionally, differences in the gut microbiome in
patients with NASH may alter intestinal permeability
through inﬂammation-based and bacterial metabolite-
driven pathways.4,6 The potential contribution of liver pa-
thology to intestinal permeability in NASH, however, has yet
to be investigated.
In an effort to comprehensively assess the rates of
increased intestinal permeability in patients with and
without NASH, we performed a meta-analysis of literature
examining this question. We then sought to mechanistically
explain the association between intestinal permeability and
NASH using an animal model for NASH as a means to
eliminate possible confounders of the clinical data, such as
antibiotic exposure and medical comorbidities. We focused
our attention on the potential contribution of liver injury to
intestinal permeability, as we hypothesized that an initial
liver injury may lead to systemic disturbances, including an
increase in intestinal permeability, which further propa-
gates liver inﬂammation.Materials and Methods
Meta-analysis
We performed a meta-analysis to compare the rates of
increased intestinal permeability in patients with and
without NAFLD. For inclusion in the meta-analysis, a study
had to meet the following criteria: 1) measurement in vivo
of intestinal permeability with a validated test substance
(monosaccharide, nonhydrolyzed or hydrolyzed disaccha-
ride, 51Cr-EDTA, or 99mTc-DTPA); 2) documentation of
NAFLD with imaging or histology; 3) documentation of
minimal to no alcohol use in both groups; and 4) lack of
coexisting liver disease in both groups.
To ﬁnd relevant articles, a systematic review of English
and non-English articles was performed using PubMed
(1946 to July 2014) and EMBASE (1988 to 2014 week 15).
The PubMed search was performed by the authors (J.L.,
M.D., and S.J.P.), and an information library specialist at the
Mayo clinic library performed the EMBASE search. To
reduce reporting bias and error in data collection, twoindependent reviewers (J.L. and S.J.P.) extracted data from
selected studies using standardized data extraction forms.
We contacted the primary investigators of articles with
questions that arose during data extraction. We identiﬁed
additional studies by searching bibliographies of all the
reviewed articles and abstracts presented at the Digestive
Disease Week and the Liver Meeting from 2007 to 2014. We
used crude odds ratio (OR) for increased intestinal perme-
ability, comparing NAFLD patients to controls as our
parameter of interest. We pooled estimates by random-
effects meta-analysis according to the method of DerSimo-
nian and Laird7 and ﬁxed-effect meta-analysis by calculating
the weighted average of study estimates with the inverse of
estimates variance used as the study weight. Q statistic and
I2 values were estimated to evaluate the heterogeneity
among the studies.8
We used Comprehensive Meta-Analysis software for
these analyses. The methodological quality of the studies
was assessed by two investigators (J.L. and S.J.P.) indepen-
dently using the Newcastle-Ottawa scale.9 For meta-
analyses of a small number of studies (generally less than
10), the power to detect publication bias is poor and is not
recommended.10In Vivo Induction of Nonalcoholic Steatohepatitis
Male C57/BL6 mice aged 8 to 10 weeks were obtained
from Jackson Laboratory (Bar Harbor, ME). To study the
role of TNF-a in NASH pathogenesis, male C57/BL6 mice
genetically deﬁcient in the long isoform of myosin light
chain kinase (MLCK) were used. All animal experiments
were reviewed and approved by the Massachusetts General
Hospital and the University of Chicago subcommittees on
research animal care. To induce NASH, mice were fed a
methionine-and-choline-deﬁcient (MCD) diet (Research Di-
ets, New Brunswick, NJ). Mice were euthanized at multiple
time points up to 21 days.Biochemical Analysis of Liver Injury
For the animal experiments, immediately after eutha-
nasia, we collected systemic blood from the inferior vena
cava. Serum was obtained by centrifugation of whole blood
at 10,000 rpm for 10 minutes. For the in vitro experiments,
cell-free culture supernatant was concentrated to 500 mL
using Microcon centrifugal ﬁlter devices (Millipore, Billerica,
MA). To determine the extent of hepatocyte injury, quanti-
ﬁcation of alanine aminotransferase (ALT) was performed
from serum and concentrated culture supernatant using the
Inﬁnity ALT Liquid Stable Reagent (Thermo Scientiﬁc,
Middletown, VA).Histologic Analysis of Liver Injury
The intact liver was excised immediately after mouse
sacriﬁce, ﬁxed in formalin for 24 hours, and then embedded
in parafﬁn. Histologic analysis was performed on liver sec-
tions stained with H&E.
The severity of liver injury was determined using the
NAFLD activity score as previously described elsewhere
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area of tissue, a steatosis score was determined by the
extent of steatosis: 0 (<5%), 1 (5%–33%), 2 (34%–66%),
and 3 (>66%). An inﬂammation score was determined
based upon the number of inﬂammatory foci in a 200
ﬁeld: 0 (0 foci), 1 (<2 foci), 2 (2–4 foci), and 3 (>4 foci). The
degree of hepatocyte ballooning was not scored as we have
not found this histologic feature to be a characteristic
ﬁnding of the MCD model. The modiﬁed NAFLD activity
score was calculated by summation of the steatosis and
inﬂammation scores. The examinations were performed in a
blinded fashion by two independent investigators (J.L.
and V.D.).
In Vivo Intestinal Permeability Assay
To measure intestinal paracellular permeability, the
serum level of ﬂuorescein isothiocyanate-4 kD dextran was
measured as previously described elsewhere.12 Brieﬂy,
mice were denied access to food and water for 8 hours
before sacriﬁce. At 4 hours before sacriﬁce, ﬂuorescein
isothiocyanate-4 kD dextran (Sigma-Aldrich, St. Louis, MO)
at a dose of 60 mg/100 g body weight was orally gavaged.
Immediately after the mice were sacriﬁced, we collected
serum and measured the ﬂuorescence intensity in serum
(excitation, 490 nm; emission, 525 nm) using the Synergy 2
plate reader (BioTek, Winooski, VT).
Immunoﬂuorescence Microscopy
The small intestine was excised and immediately placed
in optimal cutting temperature compound (Tissue Tek;
Sakura, Torrance, CA) and frozen in liquid nitrogen. We
collected 5-mm frozen sections on coated slides and ﬁxed
them with 4% paraformaldehyde. Immunostaining was
performed as previously described elsewhere.13 Brieﬂy, the
ﬁxed sections were permeabilized with 0.1% Triton X-100
in phosphate-buffered saline (PBS) for 20 minutes and
washed ﬁve times with 1% bovine serum albumin in PBS.
Zona occludens-1 (ZO-1) was localized by incubating with
rabbit anti-ZO-1 rabbit polyclonal antisera (Upstate
Biotechnology, Waltham, MA) at a 1:200 dilution for 1 hour
at room temperature. Subsequently, tissue sections were
incubated with ﬂuorescein isothiocyanate (FITC)-conju-
gated anti-rabbit IgG antibody (Sigma-Aldrich) at a 1:200
dilution for 1 hour. Standard epiﬂuorescence microscopy
was performed using a ﬂuorescence microscope (EVOS FL;
Life Technologies, Grand Island, NY).
Quantitative Real-Time Polymerase
Chain Reaction
Mouse liver tissues were mechanically homogenized
using the PowerGen 125 Homogenizer (Fisher Scientiﬁc,
Fair Lawn, NJ). Total RNA was extracted using the RNeasy
Mini Kit (Qiagen, Valencia, CA). Total RNA (500 ng) was
converted into cDNA using the RT2 First Strand Kit (SA
Biosciences, Valencia, California). Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed us-
ing the RT2 Master Mix Kit (SA Biosciences, Valencia, CA)and the iQ 5 system (Bio-Rad Laboratories, Hercules, CA).
Quantitative RT-PCR was performed for mRNA expression
of b-actin and TNF-a, interleukin-1b (IL1b), and IL6 using
primers designed by SA Biosciences (Qiagen). Expression of
b-actin was used to standardize the samples, and the results
are expressed as a ratio relative to control.Detection of Cytokines in the
Systemic Circulation
The levels of multiple cytokines (TNF-a, IL1b, and IL6)
was assessed from serum using magnetic bead-based
multiplex assays (Millipore) coupled with the Luminex-
200 System Analyzer (Luminex, Austin, TX), as recom-
mended by the manufacturer’s overnight protocol. The
mean ﬂuorescence intensity was expressed as the ratio
relative to the average mean ﬂuorescence intensity value
obtained at day 0.Cell Lines and Primary Cell Isolation
We maintained the H35 hepatocyte-derived cells as
previously described elsewhere.14 The Caco2 cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum and antibiotics (100
U/mL penicillin G and 100 U/mL streptomycin) (Life
Technologies, Grand Island, NY).
Rat Kupffer cells were separated from the non-
parenchymal cell (NPC) fraction using centrifugal elutria-
tion, as previously described elsewhere.15 Brieﬂy, the NPC
fraction was centrifuged at 300g for 15 minutes. The su-
pernatant was discarded, and the pellet was resuspended in
ice-cold PBS and passed through a cell strainer (40-mm
pore) to remove any large debris. The elutriator was ster-
ilized by circulating water (45 mL/min, 0g, 5 minutes), 6%
H2O2 (10 mL/min, 50g, 5 minutes), 15 mg/mL catalase
solution (10 mL/min, 0g, 5 minutes), sterile water
(10 mL/min, 40g, 5 minutes), and Hank’s balanced salt so-
lution (10 mL/min, 40g, 5 minutes). The elutriator was then
ramped to 600g, and a ﬂow of 10 mL/min was maintained.
We introduced 10 mL of the NPC fraction into the elutriator
and washed for 10 minutes to remove any cell debris while
we maintained the rotor at 600g. Kupffer cells were eluted
at 45 mL/min, 600g, and 100 mL of the cell suspension was
collected. The cells were pelleted at 500g for 7 minutes
(no brake) and used as an enriched fraction in experiments.In Vitro Induction of Steatohepatitis
Media identical to standard Dulbecco’s modiﬁed Eagle’s
medium culture yet deﬁcient in L-methionine and choline
chloride (Life Technologies) (MCD medium) was used to
induce steatohepatitis in vitro as previously described
elsewhere.14 Brieﬂy, H35 cells were cocultured with rat
primary Kupffer cells at a 2:1 ratio in 12-well plates in
standard medium for 24 hours, after which the standard
medium was replaced by MCD medium for 24 hours. Cell-
free culture supernatant was harvested for the ALT mea-
surement. Additionally, the protein level of TNF-a in the
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ELISA kit (eBioscience, San Diego, CA).In Vitro Intestinal Permeability Assay
To assess the effect of MCD medium on intestinal
permeability in vitro, Caco2 cells were added to the apical
side of collagen-coated Transwells (Corning, Lowell, MA).
Caco2 cells were grown for 21 days to allow for monolayer
and tight junction formation. We then added the MCD me-
dium to the culture system. After 24 hours, the intestinal
permeability was assessed by measuring the transepithelial
electrical resistance (TEER) using the Millicell-ERS electrical
resistance system (Millipore). The resistance obtained from
each experimental well was subtracted from a blank value
obtained by inserting the electrodes in a transwell
harboring a cell-fee medium. This value was multiplied by
the area of the membrane to obtain TEER (U  cm2).Statistical Analyses for In Vivo and
In Vitro Experiments
Data are expressed as mean ± standard error and
analyzed by unpaired Student t tests. Two-tailed P values
were calculated, and P < .05 was considered statistically
signiﬁcant.Results
Nonalcoholic Steatohepatitis Patients Are More
Likely to Have Increased Intestinal Permeability
Compared With Healthy Controls
The initial search strategy for the meta-analysis yielded
288 potential articles for inclusion (Supplementary Table 1).
Although there were multiple reasons for exclusion, the
most common included studies involved animals and
studies that did not directly measure intestinal permeability
but rather used a surrogate measure such as serum lipo-
polysaccharide. After analysis of the selected articles,
nine were reviewed in further detail. Subsequently, ﬁve
studies (N ¼ 128 patients) met our inclusion criteria
(Supplementary Figure 1).16–21 The characteristics of the
included studies are summarized in Table 1. Normal values
for tests measuring intestinal permeability were determined
by the included study or from previously deﬁned values.22Table 1.Characteristics of Included Nonalcoholic Fatty Liver D
Author Year Location
NAFLD
Diagnosis Intestinal
Wigg et al17 2001 Australia Histology Urinary lactulo
Farhadi et al18 2008 United States Histology Urinary lactulo
Miele et al19 2009 Italy Histology Urinary chrom
excretion o
Volynets et al20 2012 Germany Ultrasound and
serology
Urinary lactulo
Giorgio et al21 2014 Italy Histology Urinary lactuloWe found that 39.1% of NAFLD patients in our analysis
had evidence for increased intestinal permeability,
compared to 6.8% of healthy controls. The OR of NAFLD
patients having increased intestinal permeability compared
with controls was 5.08 (95% conﬁdence interval [CI],
1.98–13.05) (Figure 1A). There was minimal heterogeneity
in the included studies (I2 ¼ 9.8%, Q statistic 4.43, P ¼ .35),
which was further strengthened by an exclusion sensitivity
analysis (Figure 1B). The assessment of study quality is
outlined in Table 2.
We next performed a subgroup analysis comparing the
frequency of increased intestinal permeability in patients
with NASH with that of the healthy controls. Four of the ﬁve
studies (n ¼ 83 patients) allowed for this analysis. We found
that patients with NASH are also more likely to have
increased intestinal permeability compared to healthy con-
trols (OR 7.21; 95% CI, 2.35–22.13). The incidence of
permeability changes in this subgroup (49.2%) was higher
as compared to NAFLD patients as a whole, which includes
patients with bland steatosis (Figure 2A). Although no sta-
tistically signiﬁcant heterogeneity was detected (P ¼ .09),
there was moderate heterogeneity (I2 ¼ 54.5%) across the
studies. Interestingly, exclusion sensitivity analysis revealed
the study by Wigg et al17 markedly reduced the observed
OR (OR when excluded: 34.3; 95% CI, 28.3–161.65)
(Figure 2B). Overall, these data show that NAFLD patients,
and in particular those with NASH, are more likely to exhibit
increased intestinal permeability compared with healthy
controls.A Methionine-Choline-Deﬁcient Diet Induces
Intestinal Permeability Changes After Liver Injury
To further investigate the clinical association between
intestinal permeability and NASH, we examined this rela-
tionship in a dietary animal model (the MCD model) for
NASH. The MCD model was chosen for its well-established
ability to induce steatosis and inﬂammation and do so
reproducibly in a relatively short period of time. However, it
must be noted that the MCD model does not induce the
weight gain, lipid abnormalities, or insulin resistance that
are common in NASH patients.
We found that mice fed an MCD diet developed liver
injury rapidly, as early as 6 days into the diet, at which time
serum levels of ALT were elevated and histologic evidenceisease (NAFLD) Studies
Permeability Assay
Single versus
Multicenter NAFLD (n) Control (n)
se/rhamnose at 5 hours Single 18 16
se/mannitol at 5 hours Single 16 12
ium-51 ethylene diamine
ver 24 hours
Single 35 24
se/mannitol at 6 hours Single 20 10
se/mannitol at 6 hours Single 39 21
Figure 1. Meta-analysis of increased intestinal permeability
rates in nonalcoholic fatty liver disease (NAFLD) patients
versus healthy controls. (A) Forest plot of increased intestinal
permeability in patients with NAFLD as compared to healthy
controls using a ﬁxed-effects model. (B) Exclusion sensitivity
plot of increased intestinal permeability in NAFLD patients
versus healthy controls. CI, conﬁdence interval; OR, odds ratio.
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(Figure 3A–C). This early phase of liver injury and inﬂam-
mation was followed by a secondary phase of injury, withTable 2.Newcastle-Ottawa Scale for Assessment of Quality of
Quality Assessment Criteria
Is the case deﬁnition adequate? (Yes, with independent
validation)
Representatives of cases? (Consecutive or obviously
representative series of cases)
Selection of controls? (Community controls)
Deﬁnition of controls? (No history of studied end point)
Study controls for age/sex? (Matching or multivariable analysis)
Study controls for at least three additional factors?
Ascertainment of exposure? (Secure record, structured interview
by health-care practitioner, blind to case/control status)
Same method of ascertainment of cases/controls? (Yes)
Nonresponse rate? (Same for both groups)
Total overall score (Maximum ¼ 9)peak ALT and histologically based modiﬁed NAFLD activity
scores occurring at day 21. In parallel, we found that both
hepatic and systemic levels of TNFa rose at an early time
point with a subsequent secondary rise at day 21 (Figure 3D
and E). Interestingly, we were unable to detect a difference
in hepatic or systemic levels of IL6 or IL1b over the 21-day
course, suggesting that these cytokines, which have been
implicated in NASH pathogenesis, may contribute to a later
phase of injury and inﬂammation.23,24
We next examined the temporal pattern of intestinal
permeability changes during the course of the MCD diet.
Although permeability steadily increased as the experiment
progressed, a signiﬁcant increase in intestinal permeability,
as measured by both the serum signal intensity of FITC-
dextran, was not observed until day 10 (Figure 3F), well
after the initial phase of liver injury, inﬂammation, and
TNFa production. Furthermore, we ﬁrst noted evidence for
disruption of ZO-1 localization in the small intestine at day
10, suggesting injury to the epithelial tight junction complex.
These ﬁndings are consistent with the clinical association
between increased intestinal permeability and NASH, but
suggest that increased intestinal permeability is an effect
rather than cause of NASH. One potential explanation could
be that an initial phase of hepatic injury and inﬂammation
releases intermediates, such as cytokines, that increase in-
testinal permeability, and that the latter further contribute
to the progression of liver injury.
Methionine and Choline Deﬁcient Culture
Medium Directly Induces Hepatocyte Injury and
Inﬂammation but Does Not Affect Intestinal
Epithelial Paracellular Permeability
To address our in vivo observation of early liver injury
and TNFa production subsequently inﬂuencing intestinal
permeability, we studied the effect of MCD medium on he-
patocytes, Kupffer cells, and intestinal epithelial cells
in vitro. We cocultured rat hepatocytes (H35 cells) and
primary rat Kupffer cells together in an attempt to moreIncluded Studies
Wigg
et al17
Farhadi
et al18
Miele
et al19
Volynets
et al20
Giorgio
et al21
þ þ þ þ þ
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Figure 2. Meta-analysis of increased intestinal perme-
ability rates in nonalcoholic steatohepatitis (NASH) pa-
tients versus healthy controls. (A) Forest plot of increased
intestinal permeability in patients with NASH as compared
with healthy controls using a ﬁxed-effects model. (B) Exclu-
sion sensitivity plot of increased intestinal permeability in
NASH patients versus healthy controls. CI, conﬁdence inter-
val; OR, odds ratio.
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within the liver. We found that exposing hepatocytes and
Kupffer cells to MCD medium induced signiﬁcant hepatocyte
injury and TNFa production as compared with cells grown
in standard medium (Figure 4A and B). These data rein-
forced our in vivo observation that MCD directly induces
liver injury and inﬂammation.
In contrast, we did not observe any deleterious effect of
exposing intestinal epithelial cells to MCD medium. Specif-
ically, intestinal epithelial cells exposed to the MCD medium
showed no reduction in TEER, suggesting that the MCD
medium does not directly disrupt intestinal tight junction
function. Taken together, these in vitro data show that MCD
medium induces hepatocyte injury and TNFa production
yet does not independently disrupt intestinal epithelial
tight junction function, suggesting that our in vivo obser-
vation of increased intestinal permeability in the MCD
model may rely on MCD-induced hepatic injury and TNFa
production.Mice Resistant to TNFa-Induced Intestinal
Permeability Changes Develop Signiﬁcant
Intestinal Permeability and Liver Injury When Fed
a NASH-Inducing Diet
Our data thus far suggest that MCD-induced hepatic
TNFa production may play a role in altering intestinal
permeability and contribute to ongoing liver injury and
inﬂammation. To test this hypothesis, we exposed mice
deﬁcient in the long isoform of myosin light chain kinase
(MLCK) to the MCD diet. These mice are resistant to acute-
TNFa-induced intestinal permeability increases13,25 and
also are protected from barrier loss in experimental in-
ﬂammatory bowel disease.26 We hypothesized that long
MLCK-deﬁcient mice would exhibit early hepatic injury
induced by the MCD diet but be protected against intestinal
permeability changes and ongoing hepatic injury and
inﬂammation.
However, we found that MCD-fed MLCK-deﬁcient mice
developed equally signiﬁcant liver injury compared with
wild-type mice fed an MCD diet for 21 days (Figure 5A and
B). Furthermore, long MLCK-deﬁcient mice exhibited
increased intestinal permeability compared with the MLCK-
deﬁcient mice fed a standard chow (Figure 5C). Taken
together, these data strongly suggest that TNFa is not pre-
dominantly responsible for the observed changes in intes-
tinal permeability seen during the MCD diet.
Discussion
In this study we demonstrate that NAFLD patients, and
in particular patients with NASH, are more likely to exhibit
increased intestinal permeability compared with healthy
controls. We correlate this clinical observation with in vivo
data showing that MCD-fed mice develop intestinal perme-
ability changes after an initial phase of liver injury and TNFa
induction.
In vitro studies reveal that MCD medium induces hepatic
injury and TNFa production yet has no direct effect on in-
testinal epithelial cells. Although these data suggest a role
for hepatic TNFa in altering intestinal permeability, we
found that MCD-fed mice genetically resistant to TNFa-
induced intestinal permeability changes were not protected
against liver injury. Taken together, our clinical and exper-
imental results strengthen the association between intesti-
nal permeability changes and NASH as well as suggest that
an early phase of hepatic injury and inﬂammation contrib-
utes to altered intestinal permeability in a TNFa- and MLCK-
independent fashion.
Although the pathogenesis of NASH is likely multifacto-
rial, there are emerging data that suggest alterations in in-
testinal permeability can contribute to liver injury. The
emergence of the “gut-liver axis” implicates changes in in-
testinal physiology in the pathogenesis of liver injury. For
example, Gabele et al3 demonstrated that induction of colitis
in mice fed a high-fat diet caused more severe steatohepatitis
as compared with mice fed a high-fat diet without colitis.
They further showed that increased intestinal translocation
of microbial products into the portal vein of colitis-affected
mice occurred, which suggests that disruption of the
Figure 3. Temporal characterization of liver injury and intestinal permeability changes in a murine dietary nonalcoholic
steatohepatitis (NASH) model. C57BL/6 mice (N ¼ 5 mice/group) were fed a diet deﬁcient in methionine and choline (MCD)
and were sacriﬁced at multiple time points up to 21 days. We found evidence for signiﬁcant MCD-induced liver injury as early
as day 6 based on both (A) serum alanine aminotransferase (ALT) and (B, C) H&E liver histology (original magniﬁcation: 20)
that progressed to a peak value at day 21. Speciﬁcally, liver histologic examination revealed a progressively increasing number
of inﬂammatory foci and steatosis throughout the experiment. In parallel, hepatic mRNA expression and systemic levels of
tumor necrosis factor-a (TNF-a) were elevated at an early phase of the diet (D, E).Temporal evaluation of intestinal permeability
changes, based on (F) ﬂuorescein isothiocyanate (FITC) dextran serum measurements, and tight junction architecture based
on (G) immunoﬂuorescence staining for zona-occludens-1 (ZO-1), revealed evidence for a signiﬁcant increase in intestinal
permeability and disruption of normal tight junction architecture (loss of chicken-wire appearance of ZO-1: arrows) at day 10.
DAPI, 40,6-diamidino-2-phenylindole.
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Figure 4. In vitro assessment of MCD-induced changes to
the liver and intestine. Rat hepatocytes (H35) were grown in
coculture with primary rat Kupffer cells (KC) at a ratio of 2:1.
Cells were exposed to standard medium (SM) or methionine-
and-choline-deﬁcient (MCD) medium for 24 hours, after
which the supernatant was harvested for further analysis. (A)
Coculturing of hepatocytes and KCs in the presence of MCD
caused the most signiﬁcant elevation in hepatocyte injury,
based on supernatant levels of alanine aminotransferase
(ALT). (B) Further, MCD-exposed hepatocytes and KCs pro-
duced signiﬁcantly more tumor necrosis factor-a (TNF-a)
compared to cells grown in standard medium. (C) Intestinal
epithelial cells (Caco2 cells) were grown to conﬂuence and
allowed to form strong tight junctions, after which they were
exposed to either MCD medium or SM. We found no differ-
ence in tight junction function between cells grown in MCD
medium versus SM, suggesting MCD medium is not directly
toxic to these cells. TEER, transepithelial electrical resistance.
Figure 5. In vivo assessment of tumor necrosis factor-a
(TNF-a) on intestinal permeability in nonalcoholic stea-
tohepatitis (NASH) pathogenesis. TNF-a-induced increases
in intestinal permeability are mediated through myosin light
chain kinase (MLCK); therefore, genetic deletion of MLCK
renders mice impervious to intestinal permeability changes
caused by TNF-a.22 We tested whether mice deﬁcient in the
long isoform of MLCK would be protected against MCD-
induced liver injury and intestinal permeability changes.
MLCK-knockout (KO) and wild-type (WT) mice were fed the
MCD diet for 24 days and then euthanized (N ¼ 5 mice per
group). There were no differences in (A) serum levels of ALT
or (B) in H&E liver histology (original magniﬁcation: 20) be-
tween MLCK-KO and WT mice. (C) Furthermore, we were
unable to detect a difference in intestinal permeability
changes between the MCD-fed MLCK-KO and WT mice.
March 2015 Intestinal Permeability and NASH 229intestinal barrier allowed proinﬂammatory substrates access
to the liver. Similarly, Henao-Mejia et al4 associated changes
in gut physiology and microbiota with elevated levels of Toll-
like receptor agonists in the portal vein and more severe
steatohepatitis in an MCD model.
In parallel with these animal data, clinical experience
also supports the notion of a gut-liver axis. Pathological
intestinal conditions with documented changes in intestinal
permeability have been associated with NASH, including
celiac disease and inﬂammatory bowel disease.27–29
Furthermore, probiotic treatment has been shown toimprove liver aminotransferases in patients with NAFLD,
suggesting a role for intestinal microbes in NASH patho-
genesis.30 On the other hand, there is less evidence sug-
gesting that end-stage liver disease or cirrhosis can affect
intestinal physiology, and the mechanism for this is
unclear.31,32
Our results further strengthen the potential role of in-
testinal permeability in the pathogenesis of NASH, but
uniquely suggest that early changes in liver physiology may
also affect intestinal homeostasis. We show that liver injury
is induced early in the course of the MCD diet, before any
change in intestinal permeability, which suggests that the
initial liver injury phase may be contributing to the
230 Luther et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 2observed intestinal permeability changes in a TNFa-inde-
pendent manner.
The mechanism by which hepatic injury may affect in-
testinal permeability, however, remains elusive. We focused
our study on TNFa as higher levels of this cytokine have
been associated with NASH in clinical studies.33–35 Addi-
tionally, its role in modulation of intestinal permeability has
been well-established through its activation of long MLCK
and the subsequent effect on tight junction perme-
ability.24,25,36,37 However, despite the initially encouraging
data implicating hepatic TNFa, ultimately it does not appear
to be responsible for altering intestinal permeability
through an MLCK-dependent mechanism.
Alternatively, another liver-produced mediator may be
responsible for the observed intestinal changes. Besides
TNFa, several other cytokines have been implicated in
altering intestinal permeability. We did not ﬁnd any differ-
ences in hepatic and systemic levels of IL1b, which can alter
intestinal permeability through an MLCK-dependent mech-
anism.38 Furthermore, there were no differences in IL6,
which has been associated with liver-related mortality.39
and can alter intestinal permeability through claudin-2
up-regulation, although there is no expected increase in
FITC-dextran permeability.40 Our ﬁndings should not un-
derscore the potential importance of these cytokines to
NASH pathogenesis, as elevated serum and hepatic levels of
IL1b have been reported at different time points in the MCD
model.41 Several other mediators, such as transforming
growth factor b and plasminogen activator inhibitor-1,
deserve study. Further investigation into identifying a
novel hepatic-produced modulator of intestinal perme-
ability is desirable.
Although the contribution of TNFa to NASH pathogen-
esis is debated,42 there are data highlighting its key role.
Tomita et al43 showed mice deﬁcient in both TNF receptors
1 and 2 developed attenuated liver steatosis and ﬁbrosis
when fed the MCD diet, implicating the TNFa/TNF-receptor-
mediated pathway in NASH pathogenesis. Koca et al44
demonstrated that administration of an antibody to TNFa
lessened the severity of steatohepatitis induced by the MCD
diet. Thalidomide, an immunosuppressant with anti-TNFa
properties, has also been shown to reduce the inﬂammatory
proﬁle induced in a murine NAFLD model.45 Furthermore,
NAFLD patients receiving etanercept, an antibody to TNF,
have signiﬁcant reductions in the AST/ALT ratio and serum
C-reactive protein levels.46
Our data demonstrate that hepatic TNFa is not respon-
sible for altering intestinal permeability through an MLCK-
dependent mechanism. It is possible, however, that TNFa
modulates intestinal permeability independent of MLCK and
tight junctions by accelerating intestinal epithelial cell
turnover.26 Additionally, it is also possible that TNFa alters
permeability through activation of TNF-receptor 1, which
has been recently been shown as important to the patho-
genesis of alcoholic liver disease.47 Therefore, the potential
role for TNFa in NASH pathogenesis and intestinal barrier
loss should not be fully discounted.
Our study does have limitations. First, deﬁning normal
values for intestinal permeability is difﬁcult and was notuniform throughout the clinical studies included in our
meta-analysis. For example, the normal value chosen for
51Cr-EDTA testing in the study by Miele et al19 of 4.88%,
which was based on the median value obtained from the
NAFLD group in the study, is higher than normal values
previously reported.48 As another example, the normal
value for lactulose-rhamnose intestinal permeability
testing of 0.18 used to analyze data from the study by
Wigg et al17 has been shown to have sensitivity and
speciﬁcity values of 78%.22 Along these lines, intestinal
permeability is difﬁcult to assess in vivo. Although multi-
ple methodologies have been used to assess permeability,
measurement of serum FITC dextran is commonly
employed. These analyses, however, may not sensitively
detect small changes in intestinal permeability to large
probes, such as FITC-dextran, and are unable to measure
paracellular permeability increases limited to small
solutes such as ions. Last, although the MCD diet as a
model for NASH is effective in recapitulating the histologic
changes seen in NASH, it does not induce weight gain,
lipid abnormalities, or insulin resistance, which are com-
mon in NASH patients. Therefore, it is difﬁcult to comment
on the potential impact of these clinical variables on our
results.
In summary, our clinical and experimental results
strengthen the association between intestinal permeability
increases and NASH and also suggest that an early phase of
hepatic injury and inﬂammation contributes to altered in-
testinal permeability in a TNFa- and MLCK-independent
fashion. As evidence continues to mount supporting the
notion of gut-liver cross-talk, further research is needed to
decipher the mechanism by which this cross-talk occurs. It
is likely that the ﬁndings of such research will have signif-
icant clinical implications for NASH patients.
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Figure 1. Flow diagram for
meta-analysis.
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Supplementary Table 1.Search Strategy and Results
No. Search Strategy Results
1 Fatty Liver/ 35,304
2 exp nonalcoholic fatty liver/ 13,602
3 (“fatty liver” or steatohepatitis or ((NAFLD or NASH) and (liver* or hepat*)) or steatohepatitides or (liver adj2 steatos*)
or “visceral steatos*”).mp. [mp¼ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui]
57,349
4 1 or 2 or 3 57,349
5 exp Intestines/ 51,8207
6 exp Intestinal Absorption/ 56,039
7 exp Permeability/ 247,453
8 (5 or 6) and 7 10,664
9 ((intestin* or bowel* or gut or gastrointestin*) and (permeab* or leakiness)).mp. 25,612
10 8 or 9 27,656
11 4 and 10 288
12 11 not (exp animals/ not exp humans/) 193
13 limit 12 to (book or book series or editorial or erratum or letter or note or addresses or autobiography or bibliography
or biography or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or
legislation or news or newspaper article or overall or patient education handout or periodical index or portraits or
published erratum or video-audio media or webcasts) [Limit not valid in Embase, Ovid MEDLINE(R),Ovid
MEDLINE(R) In-Process; records were retained]
10
14 12 not 13 183
15 remove duplicates from 14 143
Note: Database(s): EMBASE 1988 to 2014 week 15; Ovid MEDLINE In-Process and Other Non-Indexed Citations; and Ovid
MEDLINE 1946 to Present.
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